Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy and safety of the BI 10773 in type 2 diabetic
patients with renal impairment in order to provide these data for approval for BI 10773 as an
antidiabetic agent by regulatory authorities.